United Therapeutics posts record Q3 2026 revenue but EPS miss amid higher R&D spend
United Therapeutics reported third‑quarter 2026 total revenue of $832.5 million, up 4 % year‑over‑year, driven by growth in its Tyvaso DPI product. Net income fell 24 % to $258.6 million, resulting in diluted EPS of $5.71, below analyst expectations. The company attributed the earnings shortfall to a $279.2 million R&D charge, including costs from the Thymmune acquisition, and announced a $2 billion share‑repurchase program. CEO Martine Rothblatt highlighted expanding opportunities in cardiopulmonary and respiratory therapies.
Why it matters
The revenue beat and record Tyvaso sales suggest strong commercial momentum, but the EPS miss and higher R&D outlay may pressure short‑term earnings per share. The $2 billion buyback program signals confidence in cash generation and could support the stock price, as noted in the earnings release.
Key facts
- 1Total revenues for Q3 2026 were $832.5 million, a 4 % increase from $799.5 million in Q3 2025. sec.gov
- 2Net income for the quarter was $258.6 million, down 24 % from $338.7 million a year earlier. sec.gov
- 3Diluted earnings per share were $5.71, compared with $7.16 a year ago. sec.gov
- 4Research and development expense was $279.2 million, up 119 % year‑over‑year. sec.gov
- 5Tyvaso DPI product sales were $378.5 million, a 13 % increase year‑over‑year. sec.gov
- 6The company authorized a $2 billion share‑repurchase program. stocktitan.net
Summary written by AlphAI AI Desk from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.